The Marlborough, Massachusetts-based medical technology firm reported net income of $672 million, or 45 cents per share, up from $562 million in the year-ago period. Adjusted earnings reached 80 cents per share, edging past the 78-cent consensus reported by FactSet. This performance was underpinned by a 16% surge in total sales to $5.29 billion, slightly ahead of Wall Street projections.
In section Market Quotes
Boston Scientific Beats Estimates but Shares Slide on 2026 Outlook
Boston Scientific reported a double-digit rise in fourth-quarter revenue and earnings on Wednesday, fueled by strong demand for cardiovascular devices, though shares retreated as its long-term forecast failed to satisfy high investor expectations.
Segment Performance and Future Guidance
The company’s cardiovascular division led the expansion, with revenue climbing 18% to $3.48 billion. The MedSurg unit also performed well, posting a 12% increase to reach $1.81 billion. For the first quarter, the company is targeting adjusted earnings between 78 and 80 cents per share, with organic sales growth—which strips out the impact of acquisitions and currency fluctuations—expected to land between 8.5% and 10%.Looking further ahead, Boston Scientific issued a forecast for 2026, projecting adjusted earnings of $3.43 to $3.49 per share. While this represents a significant increase from the $3.06 anticipated for 2025, the outlook appeared to underwhelm some corners of the market. Shares fell 8.3% to $83.98 in premarket trading, suggesting that investors had priced in an even more robust growth trajectory.
Comments (0)
No comments yet. Be the first!